Gerald L. Andriole
Research Subjects
Gerald L. Andriole has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Ramiro Castro
GlaxoSmithKline, Bryn Mawr, PA
6 shared publications- Stephen J. Freedland
Department of Urology, Cedars-Sinai Medical Center, Los Angeles, USA
6 shared publications Eric H. Kim
Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO
5 shared publications- Daniel Martins Moreira
Department of Urology, University of Illinois at Chicago, Chicago, IL, USA
4 shared publications Michael Marberger
Department of Urology, Medical University of Vienna, Vienna, Austria
4 shared publicationsDavid G. Bostwick
Bostwick Laboratories, Glen Allen, VA
3 shared publications
Latest Publications
- 1 February 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (2) , 92-95
Should men undergo MRI before prostate biopsy – CON
- 1 February 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (2) , 92-95
Should men undergo MRI before prostate biopsy – CON
- 1 November 2019
- Published by Elsevier in The Lancet Oncology
- Vol. 20 (11) , e608-E608
What is the best PET target for early biochemical recurrence of prostate cancer?
- 1 November 2019
- Published by Elsevier in The Lancet Oncology
- Vol. 20 (11) , e608-E608
What is the best PET target for early biochemical recurrence of prostate cancer?
- 1 February 2019
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 201 (2) , 322-331
The Impact of Positron Emission Tomography with 18 F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial
The prospective, multicenter LOCATE (F Fluciclovine [FACBC] PET/CT in Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of positron emission tomography/computerized tomography with F-fluciclovine on treatment plans in patients with biochemical recurrence of prostate cancer after primary therapy with curative intent. Men who had undergone curative intent treatment of histologically confirmed prostate cancer but who were suspected to have recurrence based on rising prostate specific antigen levels were enrolled prospectively. Each man had negative or equivocal findings on standard of care imaging. F-fluciclovine positron emission tomography/computerized tomography was performed according to standardized protocols. Treating physicians completed a questionnaire regarding the patient treatment plan before and after scanning, recording changes to the treatment modality (eg salvage radiotherapy to systemic androgen deprivation therapy) as major and changes in a modality (eg modified radiotherapy fields) as other. Between June 2016 and May 2017, 213 evaluable patients with a median age of 67 years and median prostate specific antigen 1.00 ng/ml were enrolled in study. F-fluciclovine avid lesions were detected in 122 of the 213 patients (57%). Overall 126 of the 213 patients (59%) had a change in management after the scan, which were major in 98 of 126 (78%) and in 88 (70%) were informed by positive positron emission tomography/computerized tomography findings. The most frequent major changes were from salvage or noncurative systemic therapy to watchful waiting (32 of 126 cases or 25%), from noncurative systemic therapy to salvage therapy (30 of 126 or 24%) and from salvage therapy to noncurative systemic therapy (11 of 126 or 9%). F-fluciclovine positron emission tomography/computerized tomography detected 1 or more recurrence sites in the majority of men with biochemical recurrence, frequently resulting in major changes to management plans. Future studies will be planned to determine whether a management change leads to improved outcomes.
- 1 February 2019
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 201 (2) , 322-331
The Impact of Positron Emission Tomography with 18 F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial
The prospective, multicenter LOCATE (F Fluciclovine [FACBC] PET/CT in Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of positron emission tomography/computerized tomography with F-fluciclovine on treatment plans in patients with biochemical recurrence of prostate cancer after primary therapy with curative intent. Men who had undergone curative intent treatment of histologically confirmed prostate cancer but who were suspected to have recurrence based on rising prostate specific antigen levels were enrolled prospectively. Each man had negative or equivocal findings on standard of care imaging. F-fluciclovine positron emission tomography/computerized tomography was performed according to standardized protocols. Treating physicians completed a questionnaire regarding the patient treatment plan before and after scanning, recording changes to the treatment modality (eg salvage radiotherapy to systemic androgen deprivation therapy) as major and changes in a modality (eg modified radiotherapy fields) as other. Between June 2016 and May 2017, 213 evaluable patients with a median age of 67 years and median prostate specific antigen 1.00 ng/ml were enrolled in study. F-fluciclovine avid lesions were detected in 122 of the 213 patients (57%). Overall 126 of the 213 patients (59%) had a change in management after the scan, which were major in 98 of 126 (78%) and in 88 (70%) were informed by positive positron emission tomography/computerized tomography findings. The most frequent major changes were from salvage or noncurative systemic therapy to watchful waiting (32 of 126 cases or 25%), from noncurative systemic therapy to salvage therapy (30 of 126 or 24%) and from salvage therapy to noncurative systemic therapy (11 of 126 or 9%). F-fluciclovine positron emission tomography/computerized tomography detected 1 or more recurrence sites in the majority of men with biochemical recurrence, frequently resulting in major changes to management plans. Future studies will be planned to determine whether a management change leads to improved outcomes.
- Open Access
- 1 January 2018
- Published by Elsevier in Asian Journal of Urology
- Vol. 5 (1) , 28-32
The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
- 1 January 2018
- Published by Elsevier in Asian Journal of Urology
- Vol. 5 (1) , 28-32
Open AccessThe use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
- 10 April 2017
- Published by Springer Nature in World Journal of Urology
- Vol. 35 (10) , 1525-1530
Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations
- 10 April 2017
- Published by Springer Nature in World Journal of Urology
- Vol. 35 (10) , 1525-1530
Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations